Latest news
Adlai Nortye Wins HREC Approval for AN4035 Pan-RAS ADC Phase I Trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 07:38:27 GMTAdlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanksTipRanks · Mon, 03 Aug 2026 13:20:56 GMTAdlai Nortye (NASDAQ: ANL) secures ethics nod for AN4035 Phase I cancer trial - Stock TitanStock Titan · Mon, 03 Aug 2026 12:00:53 GMTAdlai Nortye submits clinical trial notification to Australia TGA for AN4035 - TipRanksTipRanks · Mon, 03 Aug 2026 11:53:26 GMTAdlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia - The Manila TimesThe Manila Times · Mon, 03 Aug 2026 11:19:31 GMTAdlai Nortye Announces First-in-Class AN4035 Cleared for Phase I Clinical Development as First Pan-RAS(ON) ADC to Enter the Clinic - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 11:15:00 GMT